Literature DB >> 2204281

Effects of antiglucocorticoid RU 486 on development of obesity in obese fa/fa Zucker rats.

S C Langley1, D A York.   

Abstract

The effects of RU 486 (mitepristone), an antagonist of type II glucocorticoid receptors (GR), on the development of obesity in young 5-wk-old obese fa/fa rats has been investigated. After 15 days of treatment, body composition of obese RU 486-treated rats was similar to that of lean-vehicle rats. Analysis of body composition changes showed that RU 486 effectively reversed the obesity. It stopped fat deposition in obese rats but increased protein deposition to the level of lean-vehicle rats. RU 486 prevented the development of hyperphagia and reduced gross energetic efficiency in the obese rats but had little effect on lean rats. Brown adipose tissue mitochondrial GDP binding was increased in obese rats but was reduced in lean rats by RU 486 treatment. RU 486 also reduced the elevated activity of hippocampal glycerophosphate dehydrogenase, a glucocorticoid-responsive enzyme, of obese rats to the level of lean rats. The evidence suggests that abnormal activity of glucocorticoid GR receptors or abnormal cellular responsiveness to corticosterone receptor complexes may be important in the development of obesity in the fa/fa rat.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2204281     DOI: 10.1152/ajpregu.1990.259.3.R539

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  15 in total

Review 1.  Pharmacological approaches for the treatment of obesity.

Authors:  José-Antonio Fernández-López; Xavier Remesar; Màrius Foz; Marià Alemany
Journal:  Drugs       Date:  2002       Impact factor: 9.546

2.  Mice lacking ghrelin receptors resist the development of diet-induced obesity.

Authors:  Jeffrey M Zigman; Yoshihide Nakano; Roberto Coppari; Nina Balthasar; Jacob N Marcus; Charlotte E Lee; Juli E Jones; Amy E Deysher; Amanda R Waxman; Ryan D White; Todd D Williams; Jennifer L Lachey; Randy J Seeley; Bradford B Lowell; Joel K Elmquist
Journal:  J Clin Invest       Date:  2005-12       Impact factor: 14.808

3.  Revealing a steroid receptor ligand as a unique PPARγ agonist.

Authors:  Shengchen Lin; Ying Han; Yuzhe Shi; Hui Rong; Songyang Zheng; Shikan Jin; Shu-Yong Lin; Sheng-Cai Lin; Yong Li
Journal:  Cell Res       Date:  2011-10-11       Impact factor: 25.617

4.  Sustained decreases in weight and serum insulin, glucose, triacylglycerol and cholesterol in JCR:LA-corpulent rats treated with D-fenfluramine.

Authors:  D N Brindley; P Hales; A I al-Sieni; J C Russell
Journal:  Br J Pharmacol       Date:  1992-03       Impact factor: 8.739

5.  Dynamic modeling of methylprednisolone effects on body weight and glucose regulation in rats.

Authors:  Jing Fang; Debra C DuBois; Yang He; Richard R Almon; William J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-03-11       Impact factor: 2.745

6.  The steroid RU486 induces UCP1 expression in brown adipocytes.

Authors:  Ana M Rodríguez; Andreu Palou
Journal:  Pflugers Arch       Date:  2004-08-27       Impact factor: 3.657

7.  Consequence of long-term exposure to corticosterone or dexamethasone on ethanol consumption in the adrenalectomized rat, and the effect of type I and type II corticosteroid receptor antagonists.

Authors:  C Fahlke; E Hård; C J Eriksson; J A Engel; S Hansen
Journal:  Psychopharmacology (Berl)       Date:  1995-01       Impact factor: 4.530

8.  Blockade of glucocorticoid receptors with RU486 attenuates cardiac damage and adipose tissue inflammation in a rat model of metabolic syndrome.

Authors:  Yuuri Takeshita; Shogo Watanabe; Takuya Hattori; Kai Nagasawa; Natsumi Matsuura; Keiji Takahashi; Toyoaki Murohara; Kohzo Nagata
Journal:  Hypertens Res       Date:  2015-07-09       Impact factor: 3.872

9.  Diabetes impairs hippocampal function through glucocorticoid-mediated effects on new and mature neurons.

Authors:  Alexis M Stranahan; Thiruma V Arumugam; Roy G Cutler; Kim Lee; Josephine M Egan; Mark P Mattson
Journal:  Nat Neurosci       Date:  2008-02-17       Impact factor: 24.884

10.  A novel combined glucocorticoid-mineralocorticoid receptor selective modulator markedly prevents weight gain and fat mass expansion in mice fed a high-fat diet.

Authors:  C Mammi; V Marzolla; A Armani; A Feraco; A Antelmi; E Maslak; S Chlopicki; F Cinti; H Hunt; A Fabbri; M Caprio
Journal:  Int J Obes (Lond)       Date:  2016-02-02       Impact factor: 5.095

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.